GlobeNewswire: Ekso Bionics Holdings, Inc. Contains the last 10 of 273 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T00:40:48ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/04/2839963/0/en/Ekso-Bionics-Reports-Record-Annual-Revenue-of-18-3-Million.html?f=22&fvtc=4&fvtv=20961Ekso Bionics Reports Record Annual Revenue of $18.3 Million2024-03-04T21:05:00Z<![CDATA[Sold Record Number of Annual EksoHealth Units in 2023]]>https://www.globenewswire.com/news-release/2024/02/26/2835084/0/en/Ekso-Bionics-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-March-4-2024.html?f=22&fvtc=4&fvtv=20961Ekso Bionics to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 20242024-02-26T13:00:00Z<![CDATA[SAN RAFAEL, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the fourth quarter and full year 2023 after the close of trading on Monday, March 4, 2024. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments.]]>https://www.globenewswire.com/news-release/2024/01/11/2807881/0/en/Ekso-Bionics-Announces-4-6-Million-Registered-Direct-Offering.html?f=22&fvtc=4&fvtv=20961Ekso Bionics Announces $4.6 Million Registered Direct Offering2024-01-11T13:00:00Z<![CDATA[SAN RAFAEL, Calif., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has entered into a securities purchase agreement with certain institutional investors for the purchase and sale of 2,967,742 shares of common stock at a purchase price of $1.55 per share pursuant to a registered direct offering, resulting in total gross proceeds of approximately $4.6 million before deducting placement agent commissions and other offering expenses. The closing of the offering is expected to occur on or about January 16, 2024, subject to the satisfaction of customary closing conditions.]]>https://www.globenewswire.com/news-release/2024/01/08/2805847/0/en/Ekso-Bionics-Launches-GaitCoach-Software-for-EksoNR.html?f=22&fvtc=4&fvtv=20961Ekso Bionics Launches GaitCoach Software for EksoNR2024-01-08T21:05:00Z<![CDATA[SAN RAFAEL, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced the launch of GaitCoach™, its next generation gait therapy software for EksoNR.]]>https://www.globenewswire.com/news-release/2024/01/04/2804380/0/en/Ekso-Bionics-Reports-Certain-Preliminary-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html?f=22&fvtc=4&fvtv=20961Ekso Bionics Reports Certain Preliminary Fourth Quarter and Full Year 2023 Financial Results2024-01-04T22:05:12Z<![CDATA[SAN RAFAEL, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced preliminary top line financial results for the fourth quarter and fiscal year ended December 31, 2023.]]>https://www.globenewswire.com/news-release/2023/12/12/2794717/0/en/Ekso-Bionics-Receives-CMS-Coding-Approval-for-Ekso-Indego-Personal.html?f=22&fvtc=4&fvtv=20961Ekso Bionics Receives CMS Coding Approval for Ekso Indego Personal2023-12-12T13:00:00Z<![CDATA[SAN RAFAEL, Calif., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that the Pricing, Data Analysis, and Coding (“PDAC”) contractor for the Centers for Medicare & Medicaid Services (“CMS”) has completed its review of the Ekso Indego Personal and approved use of Healthcare Common Procedure Coding System (“HCPCS”) Code K1007 to bill Medicare for such device. CMS has proposed a payment level of $94,617 for devices fitting within this code and their final payment determination is expected to be announced in February 2024 and take effect on April 1, 2024.]]>https://www.globenewswire.com/news-release/2023/11/16/2782242/0/en/Ekso-Bionics-to-Participate-at-Centers-for-Medicare-Medicaid-Services-CMS-Second-Biannual-2023-Healthcare-Common-Procedure-Coding-System-HCPCS-Public-Meeting-on-Wednesday-November-.html?f=22&fvtc=4&fvtv=20961Ekso Bionics to Participate at Centers for Medicare & Medicaid Services (CMS) Second Biannual 2023 Healthcare Common Procedure Coding System (HCPCS) Public Meeting on Wednesday, November 292023-11-16T21:05:00Z<![CDATA[SAN RAFAEL, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that the Company will participate at the Centers for Medicare & Medicaid Services’ (“CMS”) Healthcare Common Procedure Coding System (“HCPCS”) public meeting on November 29, 2023, to discuss appropriate Medicare payment for the Ekso Indego Personal.]]>https://www.globenewswire.com/news-release/2023/11/02/2772774/0/en/Centers-for-Medicare-Medicaid-Services-CMS-Codifies-Medicare-Coverage-for-Ekso-Indego-Personal.html?f=22&fvtc=4&fvtv=20961Centers for Medicare & Medicaid Services (CMS) Codifies Medicare Coverage for Ekso Indego Personal2023-11-02T20:01:00Z<![CDATA[Ruling Could Significantly Expand Use of Ekso Indego Personal in Home and Community Markets]]>https://www.globenewswire.com/news-release/2023/10/26/2767972/0/en/Ekso-Bionics-Reports-Third-Quarter-2023-Revenue-Growth-of-38.html?f=22&fvtc=4&fvtv=20961Ekso Bionics Reports Third Quarter 2023 Revenue Growth of 38%2023-10-26T20:05:00Z<![CDATA[Achieves Record Quarter of EVO Unit Sales Achieves Record Quarter of EVO Unit Sales]]>https://www.globenewswire.com/news-release/2023/10/19/2763666/0/en/Ekso-Bionics-to-Report-Third-Quarter-2023-Financial-Results-on-October-26-2023.html?f=22&fvtc=4&fvtv=20961Ekso Bionics to Report Third Quarter 2023 Financial Results on October 26, 20232023-10-19T20:05:00Z<![CDATA[SAN RAFAEL, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the third quarter 2023 after the close of trading on Thursday, October 26, 2023. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments.]]>